Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China
The NDPN policy significantly enhanced firms' innovation performance by increasing R&D investment and patent applications, though its effect on overall growth remains limited in the short term. These findings provide firm-level evidence that NDPN strengthens innovation incentives in China's biopharmaceutical industry.
Authors
- Yi Sun (ORCID: https://orcid.org/0000-0003-2342-4917)
- Xingyuan Gao (ORCID: https://orcid.org/0000-0002-3204-0336)
- Yali Zhu (ORCID: https://orcid.org/0000-0001-8387-7307)
- Ying Wang
- Jinsong Zhu (ORCID: https://orcid.org/0000-0002-6013-6140)
- Xin Li (ORCID: https://orcid.org/0000-0003-3951-8061)
- Wenmin Du
- Hongyu Yan
Institutions
- Soochow University (CN)
- Nanjing Traditional Chinese Medicine Hospital (CN)
- Changzhou No.2 People's Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-11-04
- DOI
- https://doi.org/10.3389/fpubh.2025.1705030
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- Japan Society of Physiological Anthropology
- Jiangsu Pharmaceutical Association
- National Natural Science Foundation of China